Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats

Abstract

This study hypothesizes that oral rosuvastatin, oral dienogest and intraperitoneal bevacizumab might improve endometriosis in randomly selected female Wistar albino rats with surgically endometriotic implants. Thirty female Wistar albino rats with surgically endometriotic implants were randomized into three treatment groups: oral rosuvastatin (20 mg kg/day; oral rosuvastatin group 1; n = 10), oral progesterone (dienogest group 2; n = 10) and intraperitoneal bevacizumab (2.5 mg/kg of single intraperitoneal injection of bevacizumab; bevacizumab group 3; n = 10), for 10 days. Post-treatment variables were compared. The oral rosuvastatin group showed higher reduction for the glandular epithelium and uterine vessels of histopathological scores values than the oral progesterone group (both, p < 0.017, respectively). The median glandular epithelium and uterine vessels and histopathological scores values did not show a statistically significant difference between group 1 and group 3 (p > 0.017). Endometrial thickness values and uterine volume values were more significantly reduced in the oral rosuvastatin group than the oral progesterone group (both, p < 0.017, respectively). Moreover, endometrial thickness and uterine volume values were not different in groups wecompared with group 3 (p > 0.017). In conclusion, oral rosuvastatin and intraperitoneal injection of bevacizumab may cause more significant regression of surgically endometriotic implants in rats than oral progesterone medications.

Chinese abstract

.本研究假设口服瑞舒伐他汀、口服地诺孕素及经腹腔给予贝伐单抗可改善随机选择的种植子宫内膜异位病灶的雌性wistar白鼠的子宫内膜异位情况。30只手术种植的子宫内膜异位的雌性wista白鼠随机分为三组：口服瑞舒伐他汀(20 mg kg/天；口服瑞舒伐他汀组1；n = 10), 口服孕酮（地诺孕素组2；n = 10）及腹膜内给予贝伐单抗（单次腹膜内注射贝伐珠单抗2.5 mg/kg；贝伐单抗组3；n = 10）, 持续给药10天后比较治疗后变量。与口服地诺孕素组相比, 口服瑞舒伐他汀组腺上皮及子宫血管的组织病理学评分降低明显(p＜0.017)。1组和3组的腺上皮及子宫血管组织病理学评分中位数无统计学差异(p > 0.017)。口服瑞舒伐他汀组子宫内膜厚度和子宫体积比口服孕酮组明显降低(p＜0.017)。另外, 子宫内膜厚度和子宫体积与3组相比无显著性差异 (p > 0.017)。总之, 与口服孕酮药物相比, 口服瑞舒伐他汀和腹膜内注射贝伐单抗可能导致大鼠体内种植的子宫内膜异位病灶更显著的消退。

Keywords:

• Bevacizumab
• endometriotic implants
• oral progesterone
• oral rosuvastatin

Acknowledgements

All applicable institutional guidelines fort he care and use of animals were followed.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.